Irene Aícua‐Rapún, Pascal André, Andrea O. Rossetti, Philippe Ryvlin, Andreas F. Hottinger, Laurent A. Decosterd, Thierry Buclin, Jan Novy

Irene Aícua‐Rapún, Pascal André, Andrea O. Rossetti, Philippe Ryvlin, Andreas F. Hottinger, Laurent A. Decosterd, Thierry Buclin, Jan Novy November 17, 2019

ABSTRACT

Objective

Therapeutic drug monitoring (TDM) of antiepileptic drugs (AEDs) is widely established for older generation AEDs, whereas there is limited evidence about newer AEDs. Our aim is to assess the benefit of newer generation AEDs TDM in epilepsy.

Methods

We performed a randomised, controlled trial comparing systematic with rescue TDM of lamotrigine, levetiracetam, oxcarbazepine, topiramate, brivaracetam, zonisamide, or pregabalin.… Read More...

Antje Schmidt‐Pogoda, Nadine Bonberg, Mailin Hannah Marie Koecke, Jan‐Kolja Strecker, Jürgen Wellmann, Nils‐Martin Bruckmann, Carolin Beuker, Wolf‐Rüdiger Schäbitz, Sven G. Meuth, Heinz Wiendl, Heike Minnerup, Jens Minnerup November 17, 2019

Abstract

Objective

To analyze why numerous acute stroke treatments were successful in the laboratory but failed in large clinical trials.

Methods

We searched all phase III trials of medical treatments for acute ischemic stroke and corresponding early clinical and experimental studies.… Read More...

Anna‐Märta Gustavsson, Danielle Westen, Erik Stomrud, Gunnar Engström, Katarina Nägga, Oskar Hansson November 17, 2019

Abstract

Objective

To investigate if midlife atherosclerosis is associated with different dementia subtypes and related underlying pathologies.

Methods

Participants comprised the cardiovascular cohort of the Swedish prospective population‐based Malmö Diet and Cancer Study (n=6103). Carotid plaques and intima media thickness (IMT) were measured at baseline (1991‐1994).… Read More...

Dylan M. Williams, Chris Finan, Amand F. Schmidt, Stephen Burgess, Aroon D. Hingorani November 17, 2019

Abstract

Objective

To examine whether genetic variation affecting the expression or function of lipid‐lowering drug targets is associated with Alzheimer’s disease (AD) risk, to evaluate the potential impact of long‐term exposure to corresponding therapeutics.

Methods

We conducted Mendelian randomization analyses using variants in genes that encode the protein targets of several approved lipid‐lowering drug classes: HMGCR (encoding the target for statins); PCSK9 (encoding the target for PCSK9 inhibitors e.g.… Read More...

Jong S. Kim, Kyung Bok Lee, Jong‐Ho Park, Sang Min Sung, Kyungmi Oh, Eung‐Gyu Kim, Dae‐il Chang, Yang Ha Hwang, Eun‐Jae Lee, Won‐Ki Kim, Chung Ju, Byung Su Kim, Jei‐Man Ryu, on behalf of the SAFE‐TPA Investigators November 17, 2019

Abstract

Objective

Otaplimastat is a neuroprotectant that inhibits matrix metalloproteases pathway, and reduces edema and intracerebral hemorrhage (ICH) induced by recombinant tissue plasminogen activator (rtPA) in animal stroke models. We aimed to assess the safety and efficacy of otaplimastat in patients receiving rtPA.… Read More...

Pierre Durozard, Audrey Rico, Clémence Boutiere, Adil Maarouf, Romaric Lacroix, Sylvie Cointe, Shirley Fritz, Corinne Brunet, Jean Pelletier, Romain Marignier, Bertrand Audoin November 17, 2019

Abstract

Objective

To compare response to rituximab (RTX) between adult patients positive for myelin oligodendrocyte glycoprotein (MOG) and aquaporin‐4 (AQP4) antibodies.

Methods

We prospectively studied adult patients with MOG or AQP4 antibodies who received RTX under an individualized dosing schedule adapted to the biological effect of RTX monitored by memory B‐cell measurement.… Read More...

Niamh Shaughnessy, Eva B Forman, Declan O’ Rourke, Sally Ann Lynch, Bryan Lynch November 17, 2019

Classic autosomal recessive Spinal Muscular Atrophy (SMA) is a group of disorders characterised by progressive muscular paralysis and atrophy due to degeneration of the anterior horn cells in the spinal cord and motor nuclei in the lower brainstem. SMA results from homozygous deletions or mutations in the SMN1 gene on chromosome 5q13, which encodes the survival motor neuron protein 1 leading to destruction of the anterior horn cells [1].… Read More...

Marina R. Essen, Marie N. N. Hellem, Tua Vinther‐Jensen, Cecilie Ammitzbøll, Rikke H. Hansen, Lena E. Hjermind, Troels T. Nielsen, Jørgen E. Nielsen, Finn Sellebjerg November 17, 2019

Abstract

Objectives

Huntington’s disease (HD) is an autosomal dominantly inherited neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin (HTT) gene. No disease modifying therapy exists for the treatment of patients with HD. The purpose of this study was therefore to investigate early disease mechanisms which potentially could be used as a target therapeutically.… Read More...

Andoird App
Loading...